Literature DB >> 8814300

Insulin modulation of newly synthesized apolipoproteins B-100 and B-48 in human fetal intestine: gene expression and mRNA editing are not involved.

E Levy1, D Sinnett, L Thibault, T D Nguyen, E Delvin, D Ménard.   

Abstract

We investigated insulin's effect on intestinal lipid, transport and, particularly, the biogenesis of apolipoproteins crucial to lipoprotein secretion. Adding insulin (3 mU) to the serum-free medium of cultured jejunal explants from human fetuses (17-20 weeks) reduced triglyceride and chylomicron production and inhibited apo B-48 and apo B-100 secretion. When apo B mRNA was assayed by RT-PCR and its editing by primer extension, no change was detectable following the addition of insulin. HDL lipid content, apo A-1 synthesis and RNA level were unaffected by insulin. Collectively, these results suggest that the insulin-stimulated decline in intestinal chylomicron output may involve apo B co- or post-translational modifications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814300     DOI: 10.1016/0014-5793(96)00896-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs.

Authors:  Sarah F Andres; M Agostina Santoro; Amanda T Mah; J Adeola Keku; Amy E Bortvedt; R Eric Blue; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-11-13       Impact factor: 4.052

2.  Modification in oxidative stress, inflammation, and lipoprotein assembly in response to hepatocyte nuclear factor 4alpha knockdown in intestinal epithelial cells.

Authors:  Valérie Marcil; Ernest Seidman; Daniel Sinnett; François Boudreau; Fernand-Pierre Gendron; Jean-François Beaulieu; Daniel Ménard; Louis-Philippe Precourt; Devendra Amre; Emile Levy
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

3.  Type 1 Deiodinase Regulates ApoA-I Gene Expression and ApoA-I Synthesis Independent of Thyroid Hormone Signaling.

Authors:  Jing Liu; Antonio Hernandez-Ono; Mark J Graham; Valerie Anne Galton; Henry N Ginsberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-05-05       Impact factor: 8.311

4.  Overproduction of intestinal lipoprotein containing apolipoprotein B-48 in Psammomys obesus: impact of dietary n-3 fatty acids.

Authors:  E Levy; S Spahis; E Ziv; A Marette; M Elchebly; M Lambert; E Delvin
Journal:  Diabetologia       Date:  2006-06-21       Impact factor: 10.122

Review 5.  Insights from human congenital disorders of intestinal lipid metabolism.

Authors:  Emile Levy
Journal:  J Lipid Res       Date:  2014-11-11       Impact factor: 5.922

Review 6.  Intestinal lipid absorption and transport in type 2 diabetes.

Authors:  Bruno Vergès
Journal:  Diabetologia       Date:  2022-07-30       Impact factor: 10.460

7.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.

Authors:  J Hsieh; C Longuet; C L Baker; B Qin; L M Federico; D J Drucker; K Adeli
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

8.  Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production.

Authors:  Thi Thu Trang Tran; Bárbara Graziela Postal; Sylvie Demignot; Agnès Ribeiro; Céline Osinski; Jean-Paul Pais de Barros; Agnieszka Blachnio-Zabielska; Armelle Leturque; Monique Rousset; Pascal Ferré; Eric Hajduch; Véronique Carrière
Journal:  J Biol Chem       Date:  2016-06-02       Impact factor: 5.157

9.  Astragalus polysaccharides lowers plasma cholesterol through mechanisms distinct from statins.

Authors:  Yunjiu Cheng; Kai Tang; Suhua Wu; Lijuan Liu; Cancan Qiang; Xiaoxiong Lin; Bingqing Liu
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

10.  Novel insights into the regulation of postprandial lipemia by glucagon-like peptides: significance for diabetes.

Authors:  Gerald F Watts; Dick C Chan
Journal:  Diabetes       Date:  2013-02       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.